Gingival enlargement due to Amlodipine: Case report
DOI:
https://doi.org/10.33448/rsd-v10i7.17051Keywords:
Amlodipine; Calcium channel blockers; Gingival enlargement; Periodontitis; Biofilm.Abstract
Gingival enlargement is an increase in the size of the gum mostly caused by inflammatory changes associated with the prolonged accumulation of biofilm and induced by drugs, among which calcium channel blockers such as amlodipine stands out. Amlodipine is a 3rd generation drug, commonly used to treat conditions such as hypertension, arrhythmias and angina pectoris. The prevalence recorded for amlodipine-induced gingival enlargement, in patients with heart disease, ranges between 3%. Gingival enlargement induced by amlodipine is due to an interaction between gingival fibroblasts, the biochemistry of inflammation mediators and drug metabolites. The following is a case report of a 57-year-old man, hypertensive, with amlodipine-induced gingival enlargement, and with a diagnosis of periodontitis stage 3 grade C, who underwent basic periodontal therapy treatment and amlodipine was replaced by another antihypertensive drug, additionally for the final resolution of the case, a gingivectomy and open flap scaling and root planning in recurrent pockets was performed. It is concluded that the replacement of the drug induced gingival enlargement and adequate periodontal therapy can improve the patient’s gingival health and quality of life.
References
Agrawal, A. A. (2015). Gingival enlargements: Differential diagnosis and review of literature. World Journal of Clinical Cases: WJCC, 3(9), 779.
Angelopoulos, A., & Goaz, P. (1972). Incidence of diphenylhydantoin gingival hyperplasia. Oral Surgery, Oral Medicine, Oral Pathology, 34(6), 898-906.
Banthia, R., Jain, P., Banthia, P., Belludi, S., & Jain, A. K. (2012). Amlodipine-induced gingival overgrowth: a case report. The Journal of the Michigan Dental Association, 94(9), 48-51.
Bondon‐Guitton, E., Bagheri, H., Montastruc, J. L., & Centers, F. N. o. R. P. (2012). Drug‐induced gingival overgrowth: a study in the F rench P harmacovigilance D atabase. Journal of clinical periodontology, 39(6), 513-518.
Bullon, P., Machuca, G., Angel, M., Rojas, J., Lacalle, J. R., Rios, J. V., & Velasco, E. (1995). Clinical assessment of gingival size among patients treated with diltiazem. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 79(3), 300-304.
Bullon, P., Machuca, G., Martinez‐Sahuquillo, A., Rios, J., Velasco, E., Rojas, J., & Lacalle, J. (1996). Evaluation of gingival and periodontal conditions following causal periodontal treatment in patients treated with nifedipine and diltiazem. Journal of clinical periodontology, 23(7), 649-657.
Costa, S. R., Gasparini, D., & Valsecia, M. (2003). Hiperplasia gingival fibrosa inducida por fármacos en el NEA. Universidad Nacional Del Nordeste Comunicaciones Científicasy Tecnológicas.
Dongari-Bagtzoglou, A. (2004). Drug-associated gingival enlargement. Journal of periodontology, 75(10), 1424-1431.
Fardal, Ø., & Lygre, H. (2015). Management of periodontal disease in patients using calcium channel blockers–gingival overgrowth, prescribed medications, treatment responses and added treatment costs. Journal of clinical periodontology, 42(7), 640-646.
Hatahira, H., Abe, J., Hane, Y., Matsui, T., Sasaoka, S., Motooka, Y., . . . Ohmori, T. (2017). Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. Journal of pharmaceutical health care and sciences, 3(1), 1-11.
Jorgensen, M. G. (1997). Prevalence of amlodipine‐related gingival hyperplasia. Journal of periodontology, 68(7), 676-678.
Joshi, S., & Bansal, S. (2013). A rare case report of amlodipine-induced gingival enlargement and review of its pathogenesis. Case reports in dentistry, 2013.
Karnik, R., Bhat, K. M., & Subraya Bhat, G. (2012). Prevalence of gingival overgrowth among elderly patients under amlodipine therapy at a large Indian teaching hospital. Gerodontology, 29(3), 209-213.
Khokhani, R., Chopra, P., Karnik, N., Bajan, K., Ailiani, R., Waknis, S., . . . Chawla, K. (1993). Amlodipine in mild and moderate hypertension: initial Indian experience. The Journal of the Association of Physicians of India, 41(10), 662-663.
Lafzi, A., Farahani, R. M. Z., & Shoja, M. A. M. (2006). Amlodipine-induced gingival hyperplasia. Medicina Oral, Patología Oral y Cirugía Bucal (Internet), 11(6), 480-482.
Lauritano, D., Martinelli, M., Baj, A., Beltramini, G., Candotto, V., Ruggiero, F., & Palmieri, A. (2019). Drug-induced gingival hyperplasia: An in vitro study using amlodipine and human gingival fibroblasts. International journal of immunopathology and pharmacology, 33, 2058738419827746.
Livada, R., & Shiloah, J. (2014). Calcium channel blocker-induced gingival enlargement. Journal of human hypertension, 28(1), 10-14.
Marshall, R., & Bartold, P. (1998). Medication induced gingival overgrowth. Oral diseases, 4(2), 130-151.
Mirabal, Y. Á., & Carbonell, L. O. M. (2016). Hiperplasia gingival inducida por amlodipino en paciente con periodontitis crónica. Presentación de un caso. MediCiego, 23(1), 36-42.
Morisaki, I., Dol, S., Ueda, K., Amano, A., Hayashi, M., & Mihara, J. (2001). Amlodipine‐induced gingival overgrowth: periodontal responses to stopping and restarting the drug. Special Care in Dentistry, 21(2), 60-62.
Neumann, C., Willershausen-Zönnchen, B., Klug, C., & Darius, H. (1996). Clinical assessment of periodontal conditions in patients treated with nifedipine. European journal of medical research, 1(6), 273-279.
Nishikawa, S., Tada, H., Hamasaki, A., Kasahara, S., Kido, J. i., Nagata, T., . . . Wakano, Y. (1991). Nifedipine‐induced gingival hyperplasia: a clinical and in vitro study. Journal of periodontology, 62(1), 30-35.
Padrón Chacón, R. (2014). Hipertensión arterial. Padrón Chacón R, Almarales Sierra C, Pérez Cárdenas JC, Castellanos Hernández O. Temas de Medicina en Periodoncia. La Habana: Editorial Ciencias Médicas, 69-82.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica.
Pradhan, S., & Mishra, P. (2009). Gingival enlargement in antihypertensive medication. JNMA; journal of the Nepal Medical Association, 48(174), 149-152.
Quenel, L., Keribin, P., Giran, G., Tessier, M.-H., & Lesclous, P. (2020). Amlodipine-induced gingival enlargement: A case report. Journal of stomatology, oral and maxillofacial surgery, 121(3), 308-311.
Seymour, R., Ellis, J., & Thomason, J. (2000). Risk factors for drug‐induced gingival overgrowth. Journal of Clinical Periodontology: Review article, 27(4), 217-223.
Seymour, R., Ellis, J., Thomason, J., Monkman, S., & Idle, J. (1994). Amlodipine‐induced gingival overgrowth. Journal of clinical periodontology, 21(4), 281-283.
Srivastava, A. K., Kundu, D., Bandyopadhyay, P., & Pal, A. K. (2010). Management of amlodipine-induced gingival enlargement: Series of three cases. Journal of Indian Society of Periodontology, 14(4), 279.
Sume, S. S., Berker, E., Ilarslan, Y., Ozer Yucel, O., Tan, C., Goyushov, S., . . . Tezcan, I. (2020). Elevated Interleukin‐17A expression in amlodipine‐induced gingival overgrowth. Journal of periodontal research, 55(5), 613-621.
Tavassoli, S., Yamalik, N., Çaǧlayan, F., Çaǧlayan, G., & Eratalay, K. (1998). The clinical effects of nifedipine on periodontal status. Journal of periodontology, 69(2), 108-112.
Trackman, P., & Kantarci, A. (2004). Connective tissue metabolism and gingival overgrowth. Critical Reviews in Oral Biology & Medicine, 15(3), 165-175.
Trackman, P., & Kantarci, A. (2015). Molecular and clinical aspects of drug-induced gingival overgrowth. Journal of dental research, 94(4), 540-546.
Yolcu, A., & Aydogdu, I. (2020). Amlodipine-induced gingival hypertrophy. European Journal of Internal Medicine, 78, 127-128.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Valentina Martinez Peraza; Katherine Andrea Romero Espinoza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
